CVS Health Corporation
NYSE:CVSMedical - Healthcare Plans
-$0.59 today
- Market cap
- $103.43B
- Beta
- 0.62
- P/E (TTM)
- 42.8
- EPS (TTM)
- $2.30
- Dividend yield
- 2.70%
Volume 10.71M
Average 8.19M
Returns on capital
CVS Health Corporation management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
2.4%
avg 9.3%
ROIC
4.7%
avg 5.6%
ROA
0.7%
avg 3.2%
Analysis
ROIC is currently the strongest return metric at 4.7% versus its period average of 5.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
J. David Joyner CEBS | CEO, President & Chairman | USD 6.65M | 61 | — | — |
Prem S. Shah | Executive Vice President & Group President | USD 4.38M | 46 | 88.52K | <0.01% |
Steven Hale Nelson | Executive Vice President & President of Aetna | USD 4.34M | 67 | — | — |
Tilak Mandadi | EVice President of Ventures and Chief Experience & Technology Officer | USD 3.98M | 62 | 10.13K | <0.01% |
Samrat S. Khichi | Executive VP of Corporate Affairs & Chief Legal Officer | USD 3.39M | 59 | 33.42K | <0.01% |
Brian O. Newman | Executive Vice President & Chief Financial Officer | USD 2.82M | 57 | — | — |
Heidi Capozzi | Executive Vice President & Chief People Officer | USD 1.85M | 56 | — | — |
David A. Falkowski | Executive Vice President & Chief Compliance Officer | — | — | — | — |
Gustavo A. Giraldo | Head of Markets of Healthcare Benefits | — | 54 | — | — |
James David Clark | Senior Vice President, Controller & Chief Accounting Officer | — | 61 | 27.61K | <0.01% |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Nov 6, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$2.00M
Sells
9
$345.74M
Net Transaction Value
−$343.73M
Net selling
Most Active
ROBBINS LARRY
8 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Nov 6, 26Nov 6, 2026 | Shah Prem S Direct | Buy | $2M$2,001,315.22 |
| May 21, 26May 21, 2026 | ROBBINS LARRY Indirect | Sell | $22M$22,033,620.00 |
| May 21, 26May 21, 2026 | ROBBINS LARRY Indirect | Sell | $34.6M$34,619,007.07 |
| May 20, 26May 20, 2026 | ROBBINS LARRY Indirect | Sell | $74.6M$74,559,553.50 |
| May 20, 26May 20, 2026 | ROBBINS LARRY Indirect | Sell | $14.5M$14,476,038.22 |
| May 20, 26May 20, 2026 | ROBBINS LARRY Indirect | Sell | $6.4M$6,398,204.31 |
| May 20, 26May 20, 2026 | ROBBINS LARRY Indirect | Sell | $77K$77,025.52 |
| May 19, 26May 19, 2026 | ROBBINS LARRY Indirect | Sell | $14.4K$14,372.18 |
| May 19, 26May 19, 2026 | ROBBINS LARRY Indirect | Sell | $187.3M$187,326,935.38 |
| May 8, 26May 8, 2026 | Mandadi Tilak Direct | Sell | $6.2M$6,230,378.58 |
Summary
Insiders reported 1 buys worth $2.00M and 9 sells worth $345.74M over the last 12 months. That adds up to net selling of $343.73M. ROBBINS LARRY was the most active insider with 8 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | -24.7% | +52.8% (5yr)11 analysts |
| Revenue | N/A | N/A | +7.6% | +4.6% (5yr)10 analysts |
| Net Income | N/A | N/A | -25.7% | +52.8% (5yr)10 analysts |
| EBIT | N/A | N/A | +9.3% | +16.4% (5yr)10 analysts |
Analysis
Recent growth has been strongest in EBIT at +9.3% over three years. Forward estimates point to EPS at +52.8% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does CVS Health Corporation compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about CVS's management, answered from reported figures.
Who manages CVS?
CVS Health Corporation (CVS) lists 10 active executives. The top listed executive is Brian O. Newman, Executive Vice President & Chief Financial Officer.
Are CVS insiders buying or selling?
Recent insider activity shows net selling of $160.71M.
Continue the stock analysis
Jump to another research area for this company.